Aktie A144C9 GUFIC BIOSCIENCES LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Gufic Biosciences Limited NSE India S.E.

Aktien

A144C9

INE742B01025

GUFICBIO

Markt geschlossen - NSE India S.E.
Andere Börsenplätze
 13:43:51 15.05.2024 		% 5 Tage % 1. Jan.
321,5 INR -1,56 % Intraday Chart für Gufic Biosciences Limited +1,21 % +1,60 %
25.04. Gufic Biosciences Limited genehmigt die Wiedereinsetzung verschiedener Ausschüsse CI
04.04. Gufic Biosciences gründet neue hundertprozentige Tochtergesellschaft in Dubai MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Gufic Biosciences Limited Approves Reconstitution of Various Committees
Gufic Biosciences Forms New Wholly-Owned Arm in Dubai
Gufic Biosciences Limited Incorporates Wholly Owned Subsidiary Company in Dubai
Gufic Biosciences Limited Announces Demise of Shrirang Vaidya, Independent Director, Chairman of Audit Committee and Nomination and Remuneration Committee and Member of Risk Management Committee
Gufic Biosciences Secures Patent in India
Gufic Biosciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
Gufic Biosciences Gets New Patent in India
Gufic Biosciences Forms New Pharmaceutical Subsidiary
Gufic Biosciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
Lumosa Therapeutics Co., Ltd. Approves the Exclusive Licensing Agreement with Gufic Biosciences for LT1001, A Long-Acting Analgesic Injection
Gufic Biosciences Limited announced that it has received INR 999.9 million in funding from Motilal Oswal Financial Services Limited
Gufic Biosciences Limited Approves Final Dividend for the Financial Year Ended March 31, 2023
Gufic Biosciences Limited Approves Incorporation of Wholly Owned Subsidiary in Dubai, UAE
Gufic Biosciences Granted Patent for its Invention
Gufic Biosciences Gets Nod from Australian, Brazilian Regulators for Parecoxib Sodium Lyophilized Powder
Gufic Biosciences Limited Receives Approval of TGA, Australia and the National Health Surveillance Agency, Brazil for Parecoxib 40Mg Injection
Gufic Biosciences Limited Proposes Final Dividend for the Financial Year Ended March 31, 2023
Motilal Oswal Financial to Acquire 3% Stake in Gufic Biosciences for INR1 Billion
Gufic Biosciences Limited announced that it expects to receive INR 999.9 million in funding from Motilal Oswal Financial Services Limited
Gufic Biosciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A144C9 Aktie
  4. A144C9 Aktie
  5. Nachrichten Gufic Biosciences Limited
  6. Andere Sprachen